Fig. 5: CERS2 differential isoform expression predict poor prognosis in Luminal B patients. | Cell Death & Disease

Fig. 5: CERS2 differential isoform expression predict poor prognosis in Luminal B patients.

From: Alternative splicing of ceramide synthase 2 alters levels of specific ceramides and modulates cancer cell proliferation and migration in Luminal B breast cancer subtype

Fig. 5

A Comparison of differential isoform expression of CERS2 in tumor (n = 10) and matched control (n = 10) breast tissues from Luminal B patients using full-length PC and AS1 transcript specific primers show increased AS1 expression in tumor tissue. A pictorial representation of exon/intron position and primer sites are also shown. B Immunofluorescence images and quantification of CERS2 (mean ± SD, n = 7) show elevated levels in tumor tissue as compared to normal breast tissue sections. C, D Immunoblot showing the expression of proteins corresponding to PC and AS1 transcripts from 4 pairs of Luminal B tumor and adjoining normal tissue samples (C), and 12 patient tumor samples (D). Protein corresponding to PC transcript is marked by blue asterisk, and to AS1 transcript by red asterisk. E, F Survival Analysis on Luminal B patient data (TCGA-BRCA) using univariate and multivariate Cox proportional hazards (Cox-PH) regression. Inclusion of meta-features (exon 8, flanking junctions 51135, 51134, 51126 and skipping junctions 51127, 51128) (E), in multivariate analysis significantly affect patient survival (β coefficient = −229, p < 2e−16, and C-index = 1) (F). Data in A and B were analyzed by two-tailed unpaired Student’s t-test.

Back to article page